Articles and Links

Curated resources about preserving kidney function and advancements in kidney care.

American Journal of Kidney Diseases (AJKD)

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

To clarify and support the role of SGLT2 inhibitors for treatment of type two diabetes, cardiocastulcar disease, and kidney disease, the National Kidney Foundation convened a scientific workshop with an international panel of more than 80 experts.

Read More
American Society of Nephrology (ASN): Kidney360

Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as an effective therapy for improving outcomes in diabetic and nondiabetic kidney disease. Clinical trials have demonstrated the benefits of SGLT2is for secondary prevention of adverse cardiovascular (CV) effects in patients with established atherosclerotic disease and/or heart failure with reduced ejection fraction. It is imperative for clinicians to assess the use of SGLT2is in medically eligible patients and prescribe these agents when appropriate.

Read More
WSAW-TV

First major development in 20 years to help manage chronic kidney disease

A new treatment option, FARXIGA® (dapagliflozin), has been proven to help slow the progression of CKD – a huge scientific innovation for CKD patients at risk of progression with and without T2D. This approval is the most significant advancement in the treatment of CKD in over 20 years.

Read More
Kidneymedicinejournal.org

SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials

There are few data on the absolute effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors, despite their importance in treatment decision making. We investigated absolute treatment effects according to baseline kidney disease status.

Read More
Nature.com

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike other complications of diabetes, the prevalence of diabetic kidney disease has failed to decline over the past 30 years....Sodium–glucose co-transporter 2 (SGLT2) inhibitors have a beneficial impact on many of these pathophysiological abnormalities

Read More
Nature.com

Expanding the therapy options for diabetic kidney disease

New DAPA-CKD trial analyses have confirmed the outstanding renoprotective benefits of sodium–glucose co-transporter 2 inhibitors, independently of the presence of diabetes or the stage of kidney disease. 

Read More
Healio News

SGLT-2 inhibitors may prevent AKI in older adults with type 2 diabetes

The initiation of SGLT-2 inhibitors correlated with a reduced risk of AKI in older adults with type 2 diabetes compared with other glucose-lowering medications. According to data published in the American Journal of Kidney Diseases, SGLT-2 inhibitors (SGLT-2i) may prevent AKI events.

Read More
Healio News

Sodium-glucose cotransporter-2 inhibitors, finerenone can be mixed in CKD, diabetes care

There was no significant difference in results when giving finerenone with or without sodium-glucose cotransporter-2 inhibitors to patients with type 2 diabetes and chronic kidney disease, according to a speaker at ASN Kidney Week.

Read More
Healio News

Dapagliflozin earns breakthrough therapy designation for CKD with, without type 2 diabetes

The FDA granted breakthrough therapy designation to the SGLT2 inhibitor dapagliflozin for adults with chronic kidney disease with and without type 2 diabetes, according to an industry press release.

Read More
Healio News

VIDEO: Finerenone induced reduction in albuminuria for patients with CKD, diabetes

George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about a new subgroup analysis of the FIGARO-DKD trial.

Read More
Healio News

VIDEO: Finerenone provides significant reduction in time to dialysis

In this video, George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about FIDELITY data released at ASN Kidney Week.

Read More
Frontiers in Pharmacology

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD. A series of preclinical studies revealed that MR is overactivated under diabetic conditions, resulting in promoting inflammatory and fibrotic process in the kidney.

Read More
Diathrive

New Diabetes Drug in Clinical Trials Shows Big Impact on A1c & Weight-loss

One the biggest problems with many of today’s treatment options for people with type 2 diabetes is that while they help lower blood sugar levels they can actually lead to weight gain. That’s why the early results from two clinical trials of this new drug for type 2 diabetes is significantly exciting.

Read More
Healio News

New drug therapy will change the CKD landscape

In April, the FDA approved use of dapagliflozin (Farxiga, AstraZeneca) to reduce the risk for kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.

Read More
Healio News

Improving diabetes care: A conversation with Silvio Inzucchi, MD

For Silvio E. Inzucchi, MD, a simple question from a patient who underwent coronary artery bypass graft surgery would spur an interest in clinical research that helped lead to paradigm changing discoveries.

Read More
The New England Journal of Medicine

Dapagliflozin in Patients with Chronic Kidney Disease

Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.

Read More
HCP Live

Chronic Kidney Disease Management to Include SGLT2 Inhibitors

New risk assessment tools incorporating glomerular filtration rate (GFR) and albuminuria can help manage treatment for chronic kidney disease (CKD).

Read More
Kidney360

Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics

Do SGLT-2 inhibitors really help preserve kidney function for patients with CKD? The American Society of Nephrology says YES... "It is imperative for clinicians to assess the use of SGLT2is in medically eligible patients and prescribe these agents when appropriate."

Read More
Healio

Most at-risk patients not tested for kidney disease according to clinical guidelines

"The USRDS has already shown that 92% of CKD 1-3 patients are UNAWARE that they have kidney disease. Recently a different study by the National Kidney Foundation found that 80% of patients with diabetes and/or hypertension do not receive appropriate testing for CKD. This is a huge problem if we can’t identify and communicate with the people who are most at-risk." - Dr. Richard Gibney

Read More
Healio

On World Kidney Day, nephrology community should focus on patient-centered care

"Our traditional training and practice of nephrology focus on the disease and are guided by population-based patterns. This approach, however, does not consider the unique physical, emotional and social characteristics of the person with the disease, or their values and aspirations."

Read More
Healio

Advocating for change: The power of physicians to give voice to patients

A great read on social determinants of health, story-sharing, and patient advocacy. Thank you to Rita K. Kuwahara, MD, MIH!

Read More
NEJM Catalyst

Innovative ICU Physician Care Models: Covid-19 Pandemic at NewYork-Presbyterian

Dr. Gibney shared an encouraging conversation with Barry Smith, M.D., a nephrologist with Rogosin Institute covering New York Presbyterian Hospital. Despite serving at a critical epicenter of the COVID-19 pandemic, their organization is dramatically innovating to improve outcomes and experience.

Read More
Healio

Kidney care needs a paradigm shift before the next virus strikes

We are encouraged to see the need for change in kidney care recognized in this article. Pandemics expose critical weaknesses in our health care system and doctors need to get out ahead of the problem.

Read More
Institute for Healthcare Improvement

From Sweden to Texas via the IHI National Forum: Do-It-Yourself Dialysis

A nephrologist in rural Texas heard about an innovative model of care in Sweden at the IHI National Forum. Five years later, his patients are doing their own dialysis — with half the rate of hospitalizations.

Read More
Healio News

New drugs bring dual benefits for ‘intertwined’ diabetic kidney disease, CVD

Diabetic kidney disease is the leading cause of end-stage renal disease in the U.S., and 50% of adults initiating renal replacement therapy have diabetes...Until recently, there were no proven therapies that could substantially alter the timeline to ESRD or CV death for this population. Now, new agents are upending the treatment paradigm for DKD, offering the promise of delaying or even preventing dialysis, along with significant reduction in heart failure hospitalization risk and CV death. 

Read More
Healio News

Jardiance phase 3 trial shows efficacy in patients with CKD, trial will stop early

The EMPA-Kidney trial will stop early due to evidence of Jadiance's positive efficacy among patients with chronic kidney disease...

Read More
Healio News

Report shows prevalent ESKD cases across the US nearly doubled since 2000

A newly release Morbidity and Mortality Weekly Report shows a 41.8% increase in incident end-stage kidney disease cases and a 118.7% increase in prevalent cases across the United States between 2000 and 2019.

Read More
Healio News

Patients with advanced CKD can experience improved quality of life without using dialysis

Patients with advanced chronic kidney disease who choose not to use dialysis can survive many years with improvements to their mental health, in addition to stable physical health and quality of life until late into the illness, data show. 

Read More
UpToDate

IgA nephropathy: Treatment and prognosis (Subscription Required)

IgA nephropathy (IgAN) is the most common cause of primary (idiopathic) glomerulonephritis in resource-abundant settings.
The treatment and prognosis of IgAN will be reviewed here.

Read More

Resources delivered to your inbox

Sign up below to receive more stories, encouragement, and educational resources delivered straight to your email inbox.